Post hoc pooled analysis of four phase 3 trials: nemolizumab vs placebo increased itch responders by day 2 in atopic dermatitis (10.7% vs 2.9%; n=1728) and prurigo nodularis (17.2% vs 3.7%; n=560), with early sleep improvement too.
Secondary analysisn = 2,288
Ständer et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies